Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Why Is Viking Therapeutics (NASDAQ:VKTX) Stock Down 12% Pre-Market Today?

Viking Therapeutics (NASDAQ:VKTX) shares are pulling back sharply pre-market after the company priced an upsized offering of common stock and convertible senior notes, raising dilution concerns among investors. The company priced 7,857,143 shares of common stock at $35.00 per share and $225 million in …

Nitish Kishor | 24 September 2026

MAIA Biotechnology (NYSE American:MAIA) Penny Stock Slips Pre-Market Despite Phase 3 Trial Expansion

MAIA Biotechnology (NYSE American:MAIA) shares are trading modestly lower pre-market even after the company announced it received regulatory clearance from Spain's medicines agency and Portugal's national health authority to begin screening patients for its pivotal Phase 3 THIO-104 trial in non-small cell lung cancer. …

Nitish Kishor | 24 September 2026

This NASDAQ Penny Stock Is Falling Pre-Market Despite New FDA Clearance

This NASDAQ-listed oncology medical technology company is trading lower pre-market despite announcing FDA 510(k) clearance for TriNav Advance, the newest device in its Pressure-Enabled Drug Delivery portfolio for liver embolization procedures. The decline suggests the market is treating the clearance as an incremental product …

Nitish Kishor | 24 September 2026

Why Is Acadia Pharmaceuticals (NASDAQ:ACAD) Stock Down 9% Pre-Market Today?

Acadia Pharmaceuticals (NASDAQ:ACAD) shares are falling pre-market after the company reported topline results from the Phase 2 portion of its RADIANT trial evaluating remlifanserin for Alzheimer's disease psychosis. The 60 mg once-daily dose narrowly missed the primary endpoint of change in hallucination and delusion …

Nitish Kishor | 24 September 2026

Why Is Arcturus Therapeutics (NASDAQ:ARCT) Stock Up 7% Pre-Market Today?

Arcturus Therapeutics (NASDAQ:ARCT) shares are rising pre-market after the company reported encouraging interim Phase 2 results from ARCT-810 in patients with ornithine transcarbamylase deficiency, a rare inherited disorder affecting the liver's ability to remove toxic ammonia from the blood. The therapy was generally safe …

Nitish Kishor | 24 September 2026

Why Is GRAIL (NASDAQ:GRAL) Stock Up 5% Pre-Market Today?

GRAIL (NASDAQ:GRAL) shares are trading higher pre-market after an FDA advisory panel voted favorably on its Galleri multi-cancer early detection blood test, moving the product a step closer to formal regulatory approval. The 10-member Molecular and Clinical Genetics Devices Panel voted unanimously in support …

Nitish Kishor | 24 September 2026

This NASDAQ Penny Stock Is Sinking 14% Pre-Market on a Proposed Robotics Acquisition

Healthcare Triangle (NASDAQ:HCTI) shares are sinking sharply pre-market after the company signed a non-binding letter of intent to acquire the intellectual property, trademarks and business assets of Roboticom, a Pisa, Italy-based provider of industrial robotic automation systems for precision surface treatment. The proposed deal, …

Nitish Kishor | 24 September 2026

CooperCompanies (NASDAQ:COO) Opens New Innovation Hub, Unveils Six-Product CooperVision Pipeline

CooperCompanies (NASDAQ:COO) has opened The Vision Centre, a new global innovation hub for its CooperVision business, alongside announcing six major product advancements that have been accelerated for launch over the next several years. The announcement, made September 23, 2026, spans a range of contact …

Nitish Kishor | 24 September 2026

Why Is Surgery Partners (NASDAQ:SGRY) Stock Down 8% Today?

Surgery Partners (NASDAQ:SGRY) shares are trading down sharply in Wednesday's session, giving back a large portion of their recent rally as multiple bullish analyst pieces circulated following the company's closing of an approximately $800 million divestiture of its Idaho Falls and Mountain View hospitalAssetsearlier …

Nitish Kishor | 23 September 2026

Why Is Summit Therapeutics (NASDAQ:SMMT) Stock Down Today?

Summit Therapeutics (NASDAQ:SMMT) shares are pulling back sharply in Wednesday's session, giving back part of the rally sparked by updated ivonescimab survival data from the HARMONi and Harmoni-6 datasets in lung and biliary tract cancers. That data had fueled speculation about the drug's potential …

Nitish Kishor | 23 September 2026
Support

Hi! How can we help you today?

Loading…